Although several SIRPα-CD47 inhibitors have shown a good efficacy in hematologic cancers, combination therapies with agents such as cetuximab, rituximab, azacitdine, avelumab are recommended, as the antitumor activity of SIRPα-CD47 inhibitors is less pronounced in solid tumors. This evidence concerns the gene SIRPA and hematopoietic and lymphoid cell neoplasm.